查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465007

金诺芬市场：依形式、适应症分类 - 2024-2030 年全球预测

Auranofin Market by Form (Capsule, Tablet), Indication (Seronegative Rheumatoid Arthritis, Seropositive Rheumatoid Arthritis) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年金诺芬市场规模为2.092亿美元，预计2024年将达2.1899亿美元，2030年将达2.9085亿美元，复合年增长率为4.81%。

金诺芬是一种含金口服化合物，被归类为缓解疾病抗风湿药物 (DMARD)。它被开发用于治疗类风湿性关节炎是一种以发炎和疼痛为特征的慢性自体免疫疾病。金诺芬调节免疫系统，减少发炎并减缓疾病进展。此外，其免疫调节特性促使人们研究其对抗其他自体免疫疾病和某些类型癌症的潜在功效。另一方面，儘管它具有治疗功效，但它的使用通常会仔细权衡潜在的副作用，例如肾臟和肝损伤，并且在治疗期间需要定期监测患者。金诺芬是一种治疗自体免疫疾病的独特方法，强调了平衡慢性病管理中疗效和安全性的重要性。类风湿性关节炎的盛行率不断上升，以及在抗药性不断增加的情况下对替代疗法的需求是根本驱动因素。研究进展显示金诺芬对某些癌症和寄生虫有效，这将进一步扩大市场。此外，政府和非政府对慢性病和癌症研究的资助在市场扩张中发挥重要作用。然而，与金诺芬相关的副作用，例如胃肠道紊乱和皮肤反应，限制了一些患者对其的接受度。新应用的监管障碍和临床试验的高成本也是主要挑战。探索金诺芬在肿瘤学和寄生虫学中的应用带来了巨大的成长机会。对抗药性癌症和寄生虫的功效潜力可能会开拓新的市场领域。此外，製药公司和研究机构之间旨在扩大金诺芬用途的合作也将促进进一步的成长。

主要市场统计
基准年[2023] 2.092 亿美元
预测年份 [2024] 21899万美元
预测年份 [2030] 29085万美元
复合年增长率（%） 4.81%

形式：金诺芬胶囊确保均匀分布，适合将活性剂输送到全身。

金诺芬胶囊主要被认为是专为治疗类风湿性关节炎而设计的口服治疗选择。胶囊的便利性使其适合难以服用其他剂型的患者。金诺芬胶囊可实现全身药物输送并确保全身均匀分布。金诺芬胶囊因其减少发炎、改善关节活动范围和减轻疼痛的能力而受到特别关注，其剂量和给药方案针对患者依从性和治疗效果进行了优化。金诺芬锭剂提供了一种治疗类风湿类风湿性关节炎的客製化方法，结合了易用性和精确的剂量控制。锭剂因其便携性、稳定性以及能够掺入可改善金诺芬药物动力学特征的控制释放製剂的能力而受到高度优选。这意味着体内的药物水平随着时间的推移而更加稳定，这可以改善患者的治疗效果并减少副作用。锭剂还可以促进对治疗计划的依从性，这是慢性病长期管理的重要因素。

适应症：由于发炎涉及细胞机制，金诺芬是治疗血清阳性 RA 的首选药物。

血清阴性类风湿性关节炎（RA）是类风湿性关节炎的一种亚型，患者不具有类风湿性关节炎患者中常见的类风湿因子（RF）抗体或抗环瓜氨酸胜肽（抗CCP）抗体。儘管不存在这些抗体，血清阴性 RA 仍可导致严重的发炎和损伤。金诺芬是一种口服金化合物，由于其发炎特性而被用于治疗血清阴性 RA。金诺芬透过调节免疫系统来减少发炎和疾病进展。血清阴性 RA 的金诺芬治疗方法着重于症状控制和关节损伤的预防，据我所知，缺乏特异性的生物标记给该亚型的诊断和治疗带来了挑战。血清阳性类风湿性关节炎的特征是患者血液中存在类风湿因子（RF）抗体和/或抗环瓜氨酸胜肽（抗CCP）抗体。这种类型的 RA 通常与更具侵袭性的病程相关，包括更严重的关节受累和关节外症状的更高风险。金诺芬因其在控制血清阳性 RA 方面的作用而得到认可，因为它可以抑制发炎相关的细胞机制。透过针对导致发炎细胞激素产生的特定途径，金诺芬有助于减轻受影响关节的发炎、肿胀和疼痛。虽然金诺芬不是 RA 的一线药物，但它是对传统缓解疾病抗风湿药物 (DMARD) 或生物製药不耐症或无反应的患者的一种治疗选择，并且是一种旨在减少疾病活动性和治疗效果的治疗选择。

区域洞察

在美洲，特别是在美国和加拿大，金诺芬市场受到其长期用于治疗类风湿性关节炎的推动。市场已经成熟，需求稳定，这主要是由于医疗基础设施和报销政策有利于开药。然而，来自DMARD和生物相似药等新生物製药的竞争正在加剧，市场占有率正在成为一个问题。在欧洲，重点放在成本效益和临床表现上，严格的市场监管可能会限制金诺芬的成长潜力，儘管其功效已得到证实。儘管中东市场规模较小，但由于医疗基础设施和投资的不断扩大，它被视为一个充满前景的市场。由于医疗保健系统的快速发展、患者意识的提高以及类风湿性关节炎盛行率的增加，预计亚太地区金诺芬市场将显着增长。中国和印度等人口众多且医疗环境改善的国家预计将对市场做出重大贡献。此外，随着该地区研究和开发活动的增加，预计会有新的治疗应用。

FPNV定位矩阵

FPNV定位矩阵对于评估Auranofin市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对 Auranofin 市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，以获得市场竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估及资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.Auranofin市场的市场规模和预测是多少？

2.Auranofin市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3. 金诺芬市场的技术趋势和法规结构是什么？

4.金诺芬市场主要供应商的市场占有率是多少？

5. 进入金诺芬市场合适的形式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 类风湿性关节炎盛行率上升以及对替代治疗的需求
      • 金诺芬对寄生虫感染疾病、某些癌症和抗病毒药物具有潜在作用
      • 政府和非政府资助慢性病和癌症研究
    • 抑制因素
      • 与金诺芬相关的副作用
    • 机会
      • 探索金诺芬在新治疗应用的有效性
      • 製药公司与研究机构的合作
    • 任务
      • 复杂的监管环境和高成本
  • 市场区隔分析
    • 形式：金诺芬胶囊的相容性，可将活性药物输送到全身并确保均匀分布
    • 适应症：由于涉及发炎的细胞机制，金诺芬是治疗血清阳性 RA 的首选药物
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 金诺芬市场：依形式

  • 胶囊
  • 药片

第七章 金诺芬市场：依适应症分类

  • 血清阴性类风湿性关节炎
  • 血清阳性类风湿性关节炎

第八章 金诺芬美洲市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章 亚太地区金诺芬市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲金诺芬市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • 关节炎基金会投资 110 万美元用于顽固性类风湿性关节炎研究
  • 战略分析和建议

第十二章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-F97DD5A7D98B

[191 Pages Report] The Auranofin Market size was estimated at USD 209.20 million in 2023 and expected to reach USD 218.99 million in 2024, at a CAGR 4.81% to reach USD 290.85 million by 2030.

Auranofin is a gold-containing, orally administered compound classified as a disease-modifying antirheumatic drug (DMARD). It was specifically designed for the treatment of rheumatoid arthritis, a chronic autoimmune situation characterized by inflammation and pain in the joints. Auranofin works by modulating the immune system to decrease inflammation and slows the progression of the disease. Additionally, its immunoregulatory properties have spurred research into its potential efficacy against other autoimmune disorders and certain types of cancer. Despite its therapeutic benefits, its use is often carefully weighed against potential side effects, including renal and hepatic impairment, necessitating regular monitoring of patients under treatment. Auranofin represents a unique approach to managing autoimmune diseases, emphasizing the importance of balancing efficacy with safety in chronic disease management. The rising prevalence of rheumatoid arthritis and the need for alternative treatments amidst growing drug resistance are fundamental growth drivers. Advances in research demonstrating auranofin's efficacy against certain cancers and parasites further expand its market. Moreover, governmental and non-governmental funding for chronic diseases and cancer research plays a significant role in market expansion. However, side effects associated with auranofin, such as gastrointestinal issues and dermatological reactions, limit its acceptability among some patients. Regulatory hurdles and the high cost of clinical trials for new applications are significant challenges. The exploration of Auranofin's application in oncology and parasitology presents significant growth opportunities. Its potential effectiveness against drug-resistant cancers and parasites could open new market segments. Additionally, partnerships between pharmaceutical companies and research institutions aimed at expanding Auranofin's applications could spur further growth.

KEY MARKET STATISTICS
Base Year [2023] USD 209.20 million
Estimated Year [2024] USD 218.99 million
Forecast Year [2030] USD 290.85 million
CAGR (%) 4.81%

Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution

Auranofin in capsule form is a recognized oral treatment option primarily designed for the management of rheumatoid arthritis. The convenience of capsule administration makes it suitable for patients who may have difficulty with other forms of medication. Auranofin capsules provide a systemic delivery of the active drug, ensuring a uniform distribution throughout the body. This form is particularly noted for its effectiveness in reducing inflammation, improving joint mobility, and decreasing pain with a dosage and administration schedule that is optimized for patient compliance and therapeutic efficacy. The tablet form of auranofin offers a tailored approach to the treatment of rheumatoid arthritis, combining ease of use with precise dosage control. Tablets are highly favored for their portability, stability, and ability to incorporate controlled-release formulations, which can improve the pharmacokinetic profile of auranofin. This means a more consistent drug level in the body over time, potentially leading to improved patient outcomes and reduced side effects. The tablet form can also facilitate adherence to treatment schedules, an important factor in the long-term management of chronic conditions.

Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.

Seronegative rheumatoid arthritis (RA) refers to a subtype of rheumatoid arthritis where the blood of the patient does not contain rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibodies, which are typically found in rheumatoid arthritis patients. Despite the absence of these antibodies, seronegative RA can still cause significant joint inflammation and damage. Auranofin, an oral gold compound, has been utilized in the management of seronegative RA for its anti-inflammatory properties. It functions by modulating the immune system, thus reducing the inflammation and progression of the disease. Treatment approaches with auranofin in seronegative RA emphasize controlling symptoms and preventing joint damage, acknowledging the challenges in diagnosing and managing this subtype due to the lack of specific biomarkers. Seropositive Rheumatoid Arthritis is characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies in the patient's blood. This form of RA is often associated with a more aggressive disease course, including more significant joint damage and a higher risk of developing extra-articular manifestations. Auranofin's role in managing seropositive RA has been recognized due to its capacity to inhibit cellular mechanisms involved in inflammation. By targeting specific pathways that lead to the production of pro-inflammatory cytokines, auranofin helps in reducing inflammation, swelling, and pain in affected joints. Although it is not among the first-line treatments for RA, Auranofin presents a therapeutic option for patients intolerant or unresponsive to conventional disease-modifying antirheumatic drugs (DMARDs) or biologic agents, aiming to reduce disease activity & improve the quality of life of patients with seropositive RA.

Regional Insights

In the Americas, particularly in the United States and Canada, the market for auranofin has been driven by its prolonged use in treating chronic rheumatoid arthritis. The market is mature with a stable demand, largely due to the established healthcare infrastructure and reimbursement policies favoring the drug's prescription. However, growing competition from newer biologic DMARDs and biosimilars poses challenges to its market share. In Europe, the market is highly regulated with a strong emphasis on cost-effectiveness and clinical outcomes, which could limit the growth potential of Auranofin despite its proven efficacy. The Middle East, while smaller in market size, shows promise due to growing healthcare infrastructure and investment. The Asia Pacific region is anticipated to depict significant growth for the auranofin market due to rapidly evolving healthcare systems, increasing patient awareness, and growing prevalence of rheumatoid arthritis. Countries including China and India, with their vast populations and improving healthcare settings, are expected to contribute substantially to the market. Furthermore, the region's increasing research and development activities may offer new opportunities for Auranofin in alternative therapeutic applications.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Auranofin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Auranofin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Auranofin Market, highlighting leading vendors and their innovative profiles. These include Chugai Pharmaceutical Co Ltd, LGM Pharma, Prometheus Laboratories Inc., Sebela Pharmaceuticals Inc., Taj Pharmaceuticals Limited, and Xediton Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Auranofin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Form
    • Capsule
    • Tablet
  • Indication
    • Seronegative Rheumatoid Arthritis
    • Seropositive Rheumatoid Arthritis
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Auranofin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Auranofin Market?

3. What are the technology trends and regulatory frameworks in the Auranofin Market?

4. What is the market share of the leading vendors in the Auranofin Market?

5. Which modes and strategic moves are suitable for entering the Auranofin Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of rheumatoid arthritis and the need for alternative treatments
      • 5.1.1.2. Auranofin's potential against parasitic infections, certain cancers, and as an antiviral agent.
      • 5.1.1.3. Governmental and non-governmental funding for chronic diseases and cancer research
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with Auranofin
    • 5.1.3. Opportunities
      • 5.1.3.1. Exploring auranofin's efficacy in new therapeutic applications
      • 5.1.3.2. Partnerships between pharmaceutical companies and research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscape and the high cost of clinical trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution
    • 5.2.2. Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Auranofin Market, by Form

  • 6.1. Introduction
  • 6.2. Capsule
  • 6.3. Tablet

7. Auranofin Market, by Indication

  • 7.1. Introduction
  • 7.2. Seronegative Rheumatoid Arthritis
  • 7.3. Seropositive Rheumatoid Arthritis

8. Americas Auranofin Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Auranofin Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Auranofin Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Arthritis Foundation Invests USD 1.1 Million in Refractory Rheumatoid Arthritis Research
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. AURANOFIN MARKET RESEARCH PROCESS
  • FIGURE 2. AURANOFIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AURANOFIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL AURANOFIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 20. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 21. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 22. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 25. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 26. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 28. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 29. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 30. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 31. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 32. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 33. CANADA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 34. CANADA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 35. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 36. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 37. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 38. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 39. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 40. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 41. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 42. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 44. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 54. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. CHINA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 58. CHINA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 59. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. INDIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 62. INDIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 63. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 66. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 67. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 70. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 71. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 74. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 75. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 78. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 82. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 83. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 86. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 90. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 91. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 94. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 95. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 98. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 99. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 107. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 108. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 109. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 112. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 113. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 116. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 117. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 120. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 121. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 124. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 125. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 126. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 127. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 128. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 129. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. ITALY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 132. ITALY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 133. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 134. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 136. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 140. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 141. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 142. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 143. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 144. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 145. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 146. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 147. POLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 148. POLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 149. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. QATAR AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 152. QATAR AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 153. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 154. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 155. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 156. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 157. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 158. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 160. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 167. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 168. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 169. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 172. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 173. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 176. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 178. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 179. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 180. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 181. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023